He opened doors for Indian talent in global consulting and shaped the firm’s footprint across Asia and Latin America.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on my Strong Buy rating for LLY.

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m ...

Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group of patients, potentially paving the way for it to become the second ...

INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) and Verve Therapeutics, Inc. (VERV) today announced that the tender offer to purchase all of the issued and outstanding ...

Lilly Gerrard wowed followers this week as she revealed she has become a mum. Steven Gerrard's eldest daughter took to social media on Tuesday (July 15) to welcome her first child into the world.

Tino Kadewere signs with Aris FCAris Thessaloniki has secured its new striker. Zimbabwean international Tino Kadewere (29) officially joins the Greek club from FC Nantes, where he played since ...

INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain patients with early Alzheimer's disease, reversing an initial decision ...